What changed: Essential thrombocythaemia (ET)
Every dated change on the records linked to Essential thrombocythaemia (ET), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2023 · 1
2017 · 2
- 2017Trial resultMAJIC-ETMAJIC-ET reported
Complete response at 1 year about 47% in both arms; no difference in clots, bleeding or transformation.
- 2017MilestoneMAJIC-ETMAJIC-ET: ruxolitinib not superior
Ruxolitinib matched but did not beat best available therapy after hydroxyurea failure, though it eased symptoms.
2016 · 1
2013 · 1
2005 · 3
- 2005Trial resultPT-1 (Primary Thrombocythaemia 1)PT-1 (Primary Thrombocythaemia 1) reported
Composite of thrombosis, serious haemorrhage or vascular death more frequent with anagrelide (odds ratio 1.
- 2005MilestoneJAK2 V617FJAK2 V617F found in half of ET
A milestone in how this cancer is treated.
- 2005MilestonePT-1 (Primary Thrombocythaemia 1)PT-1: hydroxyurea beats anagrelide
In 809 high-risk patients hydroxyurea plus aspirin gave fewer arterial clots, less bleeding and less progression to myelofibrosis than anagrelide plus aspirin.